Differential effects of vitamin D on upper and lower body fat-free mass: potential mechanisms

Richard Kirwan

Abstract
Vitamin D insufficiency is a global health concern and low vitamin D status is regularly associated with reduced muscle mass and sarcopenia in observational research. Recent research using Mendelian randomization (MR) has highlighted the potentially causal positive effect of serum vitamin D (25(OH)D) on total, trunk and upper body appendicular fat-free mass (FFM). However, no such effect was found in lower body FFM, a result that mirrors the outcomes of some vitamin D intervention studies. Here we review the current literature on vitamin D, muscle mass and strength and discuss some potential mechanisms for the differing effects of vitamin D on upper and lower body FFM. In particular, differences in distribution of the vitamin D receptor as well as androgen receptors, in the upper and lower body musculature, will be discussed.

Keywords Muscle mass · Mendelian randomization · 25-Hydroxyvitamin D · 25(OH)D · Sarcopenia · Lean mass · Fat-free mass

Low vitamin D status is associated with multiple chronic diseases [1] as well as reduced muscle mass and other aspects of musculoskeletal health [2, 3]. However, up to 40% of the European population is believed to suffer from vitamin D (25(OH) D) insufficiency (25(OH) D level <50 nmol/L) and while prevalence of deficiency varies by geographical location, ethnicity and multiple other factors, it is widespread enough to be considered a global health issue [4, 5].

Reduced muscle mass and in particular sarcopenia, the age-associated decline in muscle mass, strength and quality [6], are associated with a multitude of chronic conditions. These include cardiovascular disease (CVD) [7], type 2 diabetes mellitus (T2DM) [8], frailty [9], increased risk of falls and fractures [10], cognitive decline and depression [11, 12], and all-cause mortality [13]. Of particular concern, the prevalence of vitamin D deficiency is believed to be particularly high (65%) amongst older adults in the UK [14, 15]. Increased time spent indoors due to poor mobility, also related to impaired muscle function amongst older adults may lead to an even greater risk of vitamin D deficiency [16, 17], which may further contribute to the development of sarcopenia in this already at-risk group.

Recently, our research group published results from Mendelian randomization (MR) analysis which provide evidence for a potentially causal association of serum 25(OH)D with total, trunk and upper body appendicular (arm) fat-free mass (FFM) [18]. These findings are broadly in agreement with some cross-sectional, population-based studies, which have shown a positive relationship between serum vitamin D status and fat-free mass [3, 19, 20]. In a population of 127 pre-frail and frail older people (79.0 ± 7.8 y) in the Netherlands, serum vitamin D status was associated with both appendicular lean mass (ALM) (β = 0.012, P = 0.05) and physical performance (β = 0.020, P < 0.05), after adjustment for confounding factors [3]. Similarly, in an adolescent population (15.3 ± 1.9 y) with (60%) and without (40%) type 1 diabetes from Poland, serum vitamin D levels correlated positively with LBM Z-scores (r = 0.3; P = 0.020) [19]. Furthermore, in a meta-analysis of 12 studies with a total of 22,590 subjects, individuals with sarcopenia were reported to have lower blood 25(OH)D concentrations than healthy controls [20].
Additionally, some interventional studies have shown increases in muscle mass upon supplementation with vitamin D [21, 22]. Ceglia et al. investigated the effects of vitamin D supplementation (4000 IU for 4 months) in 21 mobility-limited women (78 ± 5 y). The intervention group (n = 9) was observed to experience a 10.6% ± 20.0% increase in muscle fibre cross-sectional area, compared with the placebo group which experienced a 7.4% ± 18.9% decrease (P = 0.048) [21]. In a study of 77 overweight and obese women (38 ± 8.1 y), 12 weeks of supplementation with vitamin D3 (25 μg per day) lead to a 1.8 ± 2.1 kg increase in FFM in the supplement group compared to a 0.4 ± 2.1 kg increase in the placebo group (p < 0.001) [22].

Indeed, there are a number of potential mechanisms by which vitamin D may exert its effects on skeletal muscle including the regulation of expression of genes involved in muscle growth, via the vitamin D receptor (VDR), as well as non-genomic pathways involved in skeletal muscle intracellular signaling [23]. However, of particular note from our MR analysis was the fact that genetically determined serum 25(OH)D had no statistically significant positive association with lower body appendicular (leg) FFM.

In our paper [18] we acknowledged that some cross-sectional research has revealed similar findings i.e. stronger associations between vitamin D and various measures of muscle mass or strength in the upper compared with lower body appendages [3, 24]. For example, while serum vitamin D status was associated with total ALM (β = 0.012, P = 0.05) in pre-frail and frail older people (79.0 ± 7.8 y), no statistically significant association was observed with leg lean mass alone (β = 0.009, P = 0.079) [3]. Similarly, in a sample of 419 men and women (age range 20–76 y), serum vitamin-D was observed to be associated with both isometric and isokinetic strength of the arms (P < 0.05 for all measures of elbow flexion and extension) [24]. However, serum vitamin-D was only associated with isometric strength of the legs after multivariate regression (P > 0.05 for isokinetic knee extension and flexion) [24]. It should also be noted that studies showing vitamin D supplementation improving lower body strength also exist. In a 6-month trial of vitamin D (90,000-150,000 IU per month) and calcium supplementation, those receiving supplementation experienced an increase in hip flexor strength (16.4% p = 0.0001) and knee extension strength (24.6% p = 0.0007) [25]. The discrepancy in the relationship between leg and arm muscle properties with vitamin-D deserves further consideration and here we elaborate on putative mechanisms.

**Vitamin D receptor and muscle fibre type**

Murine cell models have demonstrated that skeletal muscle is a direct target for vitamin D via the VDR, highlighting the importance of vitamin D for muscle hypertrophy [26]. VDR gene knockout (VDR -/-) mice have been observed to have smaller muscle fibre sizes [27, 28] and to have significantly weaker grip strength than controls [28] with similar effects observed due to diet-induced vitamin D deficiency [28]. In rats, overexpression of VDR is known to stimulate muscle hypertrophy through multiple potential mechanisms including increased protein synthesis, translational efficiency, ribosomal expansion and upregulation of genes related to extracellular matrix (ECM) remodeling [29]. As part of the same research study, VDR expression was quantified in human subjects who had performed whole body resistance exercise for 20 weeks and VDR expression was observed to correlate significantly with muscle hypertrophy [29]. Furthermore, it has been proposed that lower vitamin D levels in the elderly may lead to reduced expression of VDR due to downregulation of the receptor [30]. This could potentially reduce protein synthesis leading to a reduction in fat-free mass and specifically, the decline in type 2 fibres characteristic of sarcopenia [31, 32]. Skeletal muscle consists of different muscle fibre types which are broadly classified as type 1 and types 2A, 2X, and 2B, based on different myosin heavy chain (MHC) composition [33]. Indeed, vitamin D supplementation has been shown to activate VDR in skeletal muscle tissue, stimulating protein synthesis [34] and to increase the size and number of type 2A muscle fibres in older adults when supplemented daily with calcium for 3–6 months [35]. In vitamin D-insufficient women, Ceglia et al. [21] reported that 4 months of daily vitamin D3 (4000IU), lead to a 10% increase in muscle fibre size and a 30% increase in intramyonuclear VDR concentration, particularly in type 2 muscle fibres [21]. However, there was no difference between supplemented and control groups in measures of knee extension strength and short physical performance battery score, nor were there any measures of muscle mass [21].

Fibre types are known to be differentially distributed in skeletal muscle throughout the body [36]. For example biceps brachii have been reported to contain a higher proportion of type 2 fibres [37], while the knee extensors are known to have higher proportion of type 1 fibres [38]. Broadly speaking, upper body appendicular skeletal muscle has a higher proportion of type 2 fibres with a higher proportion of type 1 fibres found in human lower body appendicular muscle [36, 39]. A recent study by Srikuea et al. reported higher levels of the VDR in predominantly type 2 muscles (plantaris) compared to predominantly type 1 muscles (soleus) in a mouse model [40]. These findings may
Potential mechanisms for differential upper and lower body muscle property responses to increased serum 25(OH)D levels. Upper body skeletal muscle contains a proportionally greater proportion of type 2 muscle fibres which are known to have a higher concentration of the vitamin D receptor. Vitamin D is also associated with elevated testosterone levels which interact with skeletal muscle androgen receptors, also higher in upper body skeletal muscle. Created with BioRender.com

suggest that a factor related to fibre type composition may contribute to VDR expression in different muscles. Interestingly, in a rat model of VDR-overexpression, type 2x fibres displayed a greater content of satellite cells per fibre than controls (0.024 ± 0.007 per fibre vs. 0.014 ± 0.006 per fibre, respectively, P<0.05) [29]. Satellite cell accumulation is believed to contribute to the hypertrophic response to resistance exercise [41].

One could speculate that the greater density of VDR in type 2 muscle fibres, found in proportionally greater quantity in upper body appendicular muscle compared to lower body, may lead to the positive effect of vitamin D status on arm fat-free mass observed in our MR analysis.

Testosterone and androgen receptors

Other potential causes for discrepancies in the effect of vitamin D on upper and lower appendicular muscles should also be considered. For example, another difference between upper and lower body musculature is the content of androgen receptors (AR) which have been reported to be higher in upper-body muscles (trapezius) compared with lower body muscles (vastus lateralis) [42]. It is feasible to imagine that this difference in ARs might lead to differential effects of androgen hormones such as testosterone in upper and lower body skeletal muscle. Vitamin D is thought to play a role in the development and expression of genes in the testes [43], including the production of sex-steroid hormones such as testosterone [44]. Research using isolated human adult primary testicular cells has revealed that treatment with vitamin D3 results in an upregulation of enzymes involved in androgen production as well as an increase in testosterone synthesis [44].

In men, higher serum 25(OH)D (≥75 nmol/L) has also been associated with significantly higher levels of testosterone [45–47], an androgen hormone associated with muscle mass, and Free Androgen Index (FAI) compared to those with lower levels [46]. However, some cross-sectional research has found no such association [48] or even a negative association between serum vitamin D levels and circulating free testosterone levels [49]. Furthermore, in a trial of 54 men (mean age 49.4 years) with insufficient vitamin D levels (<50 nmol/L), daily supplementation of vitamin D (3,332 IU) for 1 year lead to significant increases in both total and free testosterone [50]. It could be speculated that the testosterone-stimulating effects of vitamin D may have a greater effect on upper body lean mass due to a potentially greater content of androgen receptors in upper body musculature [42]. Figure 1 illustrates the potential VDR and androgen receptor differences of upper and lower body skeletal muscle in response to serum 25(OH)D.

Metabolic mechanisms

Additionally, there are a number of metabolic differences between these upper and lower body muscle groups, particularly related to fat utilization. Specifically, compared to legs, arm muscles have been reported to display lower fat oxidation capacity [51], lower 3-hydroxy-acyl-CoA-dehydrogenase (HAD) activity (necessary for fatty acid oxidation) [39], lower intramyocellular lipid (IMCL) content [52], and higher exercise-induced lactate release [53]. While these factors are not directly related to fat-free mass, they highlight some considerable differences in upper and lower body skeletal muscle metabolism, which could have implications for the effects of vitamin D status on muscle size in the upper and lower extremities.

A growing body of literature highlights the importance of serum vitamin D levels in muscle mass hypertrophy and maintenance i.e. body compositional changes that are associated with lower morbidity and mortality rates [7–13]. As the aging process is known to decrease the amount of vitamin D produced in the skin [54], the elderly, a population already at considerable risk of sarcopenia [6], may be even more likely to suffer muscle loss due, in part, to vitamin D deficiency. Considering the globally widespread prevalence of vitamin D insufficiency [4, 5], methods for attaining and maintaining sufficient serum 25(OH)D levels in the population deserve investigation and implementation. Furthermore, current research highlights that lower leg muscle function in particular is associated with greater risk of some chronic diseases [55]. If it is indeed the case that vitamin D is
of less benefit to lower body muscle mass and strength, then some vitamin-D-related strategies to prevent or ameliorate sarcopenia may need to be reconsidered. The discrepancies in the effects of vitamin D on arm and leg muscle mass and strength, reported in our recent MR analysis and in observational and intervention studies warrant further investigation to better understand their potential mechanisms.

Acknowledgements The author would like to express his deepest gratitude to Dr Ian Davies (Liverpool John Moores University) for his comments and suggestions on this paper.

Author contribution RK conceived and drafted the manuscript.

Funding This work was partially supported by the Institute for Health Research at Liverpool John Moores University via a studentship for RK. RK is a recipient of the Rank Prize COVID-19 grant.

Data Availability Not applicable.

Declarations

Conflict of interest RK has received speaker’s honoraria from the British Association for Parenteral and Enteral Nutrition and fees for media content creation from Abbott and Myprotein UK.

Ethics approval Not applicable.

Consent to participate Not applicable.

Consent for publication Not applicable.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Wang H, Chen W, Li D et al (2017) Vitamin D and Chronic Diseases. Aging Dis 8(3):346–353. https://doi.org/10.14336/ad.2016.1021

2. Girgis CM (2020) Vitamin D and Skeletal Muscle: Emerging Roles in Development, Anabolism and Repair. Calcif Tissue Int 106(1):47–57. https://doi.org/10.1007/s00223-019-00583-4

3. Tieland M, Brouwer-Brolsma EM, Nienaber-Rousseau C, van Loon LJ, De Groot LC (2013) Low vitamin D status is associated with reduced muscle mass and impaired physical performance in frail elderly people. Eur J Clin Nutr 67(10):1050–1055. https://doi.org/10.1038/ejcn.2013.144

4. Cashman KD, Dowling KG, Škrabáková Z et al (2016) Vitamin D deficiency in Europe: pandemic? Am J Clin Nutr 103(4):1033–1044. https://doi.org/10.3945/ajcn.115.120873

5. Cashman KD (2020) Vitamin D Deficiency: Defining, Prevalence, Causes, and Strategies of Addressing. Calcif Tissue Int 106(1):14–29. https://doi.org/10.1007/s00223-019-00559-4

6. Cruz-Jentoft AJ, Bahat G, Bauer J et al (2019) Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 48(1):16–31. https://doi.org/10.1093/ageing/afy169

7. Bahat G, Ilhan B (2016) Sarcopenia and the cardiometabolic syndrome: A narrative review. Eur Geriatr Med 7(3):220–223. https://doi.org/10.1016/j.eurger.2015.12.012

8. Scott D, de Courten B, Ebeling PR (2016) Sarcopenia: a potential cause and consequence of type 2 diabetes in Australia’s ageing population? Med J Australia 205(7):329–333

9. Xu W, Chen T, Cai Y, Hu Y, Fan L, Wu C (2020) Sarcopenia in Community-Dwelling Oldest Old is Associated with Disability and Poor Physical Function. J Nutr Health Aging 24(3):339–345. https://doi.org/10.1007/s12603-020-1325-4

10. Schaap LA, van Schoor NM, Lips P, Visser M (2018) Associations of Sarcopenia Definitions, and Their Components, With the Incidence of Recurrent Falling and Fractures: The Longitudinal Aging Study Amsterdam. J Gerontol A Biol Sci Med Sci 73(9):1199–1204. https://doi.org/10.1093/gerona.glx245

11. Hayashi T, Umegaki H, Makino T, Cheng XW, Shimada H, Kuzuya M (2019) Association between sarcopenia and depressive mood in urban-dwelling older adults: A cross-sectional study. Geriatr Gerontol Int 19(6):508–512. https://doi.org/10.1111/ggi.13650

12. Hsu YH, Liang CK, Chou MY et al (2014) Association of cognitive impairment, depressive symptoms and sarcopenia among healthy older men in the veterans retirement community in southern Taiwan: a cross-sectional study. Geriatr Gerontol Int 14(Suppl 1):102–108. https://doi.org/10.1111/ggi.12221

13. Abramowitcz MK, Hall CB, Amodu A, Sharma D, Androga L, Hawkins M (2018) Muscle mass, BMI, and mortality among adults in the United States: A population-based cohort study. PLoS ONE 13(4):e0194697. https://doi.org/10.1371/journal. pone.0194697

14. Jolliffe DA, Hanifa Y, Witt KD et al (2016) Environmental and genetic determinants of vitamin D status among older adults in London, UK. J Steroid Biochem Mol Biol 164:30–35. https://doi.org/10.1016/j.jsbmb.2016.01.005

15. van Schoor N, Lips P (2017) Global Overview of Vitamin D Status. Endocrinol Metab Clin North Am 46(4):845–870. https://doi.org/10.1016/j.ecl.2017.07.002

16. Webb AR, Pilbeam C, Hanafin N, Holick MF (1990) An evaluation of the relative contributions of exposure to sunlight and of diet to the circulating concentrations of 25-hydroxyvitamin D in an elderly nursing home population in Boston. Am J Clin Nutr 51(6):1075–1081. https://doi.org/10.1093/ajcn/51.6.1075

17. Whitmore SE (1996) Vitamin D deficiency in homebound elderly persons. JAMA 275(11):838–839

18. Kirwan R, Isanovej M, Davies IG, Mazidi M (2021) Genetically Determined Serum 25-Hydroxyvitamin D Is Associated with Total, Trunk, and Arm Fat-Free Mass: A Mendelian Randomization Study. J Nutr Health Aging. https://doi.org/10.1007/s12603-021-1696-1

19. Wierzbicka E, Szalecki M, Płudowski P, Jaworski M, Brzozowska A (2016) Vitamin D status, body composition and glycemic control in Polish adolescents with type 1 diabetes. Minerva Endocrinol 41(4):445–455

20. Luo J, Quan Z, Lin S, Cui L (2018) The association between blood concentration of 25-hydroxyvitamin D and sarcopenia: a meta-analysis. Asia Pac J Clin Nutr 27(6):1258–1270. https://doi.org/10.6133/apjcn.201811_27(6).0013

 Springer
21. Cegla L, Niramitmahapanya S, da Silva Morais M et al (2013) A randomized study on the effect of vitamin D₃, f supplementation on skeletal muscle morphology and vitamin D receptor concentration in older women. J Clin Endocrinol Metab 98(12):E1927–1935. https://doi.org/10.1210/jc.2013-2820

22. Salehpour A, Hosseinpahan F, Shidfar F et al (2012) A 12-week double-blind randomized clinical trial of vitamin D₃, f supplementation on body fat mass in healthy overweight and obese women. Nutr J 11:78–78. https://doi.org/10.1186/1475-2891-11-78

23. Boland RL (2011) VDR activation of intracellular signaling pathways in skeletal muscle. Mol Cell Endocrinol 347(1-2):11–16. https://doi.org/10.1016/j.mce.2011.05.021

24. Grimaldi AS, Parker BA, Capizzi JA et al (2013) 25(OH) vitamin D is associated with greater muscle strength in healthy men and women. Med Sci Sports Exerc 45(1):157–162. https://doi.org/10.1249/MSS.0b013e318269c7a9

25. Moreira-Pfrimer LDF, Pedrosa MAC, Teixeira L, Lazaretti-Castro M (2009) Treatment of Vitamin D Deficiency Increases Lower Limb Muscle Strength in Institutionalized Older People Independently of Regular Physical Activity: A Randomized Double-Blind Controlled Trial. Annals of Nutrition and Metabolism 54(4):291–300. https://doi.org/10.1159/000253874

26. van der Meijden K, Bravenboer N, Dirks NF et al (2016) Effects of vitamin D receptor gene in mice results in abnormal skeletal muscle development with deregulated expression of myoregulatory transcription factors. Endocrinology 144(12):5138–5144

27. Girgis CM, Cha KM, Houweling PJ et al (2015) Vitamin D receptor ablation and vitamin D deficiency result in reduced grip strength, altered muscle fibers, and increased myostatin in mice. Calcif Tissue Int 97(6):602–610

28. Bass JJ, Nakhuda A, Deane CS et al (2020) Overexpression of the vitamin D receptor (VDR) induces skeletal muscle hypertrophy. Mol Metab 42:101059. https://doi.org/10.1016/j.molmet.2020.101059

29. Bischoff-Ferrari H, Borchers M, Gudat F, Dürümüller U, Stühelin H, Dick W (2004) Vitamin D Receptor Expression in Human Muscle Tissue Decreases With Age. J Bone Miner Res 19(2):265–269. https://doi.org/10.1359/jbmr.2004.19.2.265

30. Sörensen OH, Lund B, Saltin B et al (1979) Myopathy in bone loss of ageing: improvement by treatment with 1-alpha-hydroxycholecalciferol and calcium. Clin Sci (Lond) 56(2):157–161. https://doi.org/10.1042/cs0560157

31. Sörensen OH, Lund B, Saltin B et al (1979) Myopathy in bone, tendon and muscle of the elderly population: current status and perspectives. Archives of public health 72(1):1–10

32. Sörensen OH, Lund B, Saltin B et al (1979) Myopathy in Bone Loss of Ageing: Improvement by Treatment with 1α-hydroxycholecalciferol and Calcium. Clin Sci 56(2):157–161. https://doi.org/10.1042/cs0560157

33. Johnson MA, Polgar J, Weightman D, Appleton D (1973) Data on the distribution of fibre types in thirty-six human muscles. An autopsy study. J Neurol Sci 18(1):111–129. https://doi.org/10.1016/0022-510x(73)90023-3

34. Bruyère O, Cavalier E, Souberbielle J-C et al (2014) Effects of testosterone on muscle mass and strength in aging men. J Gerontol A Biol Sci Med Sci 50 Spec No 11–16. https://doi.org/10.1093/gerona/50a.special_issue.11

35. Sørensen OH, Lund B, Saltin B et al (1979) Myopathy in bone, tendon and muscle of the elderly population: current status and perspectives. Archives of public health 72(1):1–10

36. Klein CS, Marsh GD, Petrella RJ, Rice CL (2003) Muscle fiber number in the biceps brachii muscle of young and old men. Muscle Nerve 28(1):62–68. https://doi.org/10.1016/s0022-1303(02)83686-4

37. Travník L, Pernus F, Erzen I (1995) Histochemical and morphometric characteristics of the normal human vastus medialis longus and vastus medialis obliquus muscles. J Anat 187(Pt 2):403–411

38. Ortenblad N, Nielsen J, Boushel R, Söderlund K, Saltin B, Holmberg HC (2018) The Muscle Fiber Profiles, Mitochondrial Content, and Enzyme Activities of the Exceptionally Well-Trained Arm and Leg Muscles of Elite Cross-Country Skiers. Front Physiol 9:1031. https://doi.org/10.3389/fphys.2018.01031

39. Srikuaea R, Hirunsai M, Charoenphandhu N (2020) Regulation of vitamin D system in skeletal muscle and resident myogenic stem cell during development, maturation, and ageing. Sci Rep 10(1):8239. https://doi.org/10.1038/s41598-020-65067-0

40. Verdijk LB, Snijders T, Drost M, Delhaas T, Kadi F, van Loon LJ (2014) Satellite cells in human skeletal muscle; from birth to old age. AGE 36(2):545–557. https://doi.org/10.1007/s11357-013-9583-2

41. Kadi F, Bonnerud P, Eriksson A, Thornell LE (2000) The expression of androgen receptors in human neck and limb muscles: effects of training and self-administration of androgenic-anabolic steroids. Histochem Cell Biol 113(1):25–29. https://doi.org/10.1007/s004180050003

42. Cito G, Cocci A, Micelli E et al (2020) Vitamin D and Male Fertility: An Updated Review. World J Mens Health 38(2):164–177. https://doi.org/10.1553/wmjnh.190057

43. Hofer D, Münzker J, Schwartz V et al (2014) Testicular synthesis and vitamin D action. J Clin Endocrinol Metab 99(10):3766–3773. https://doi.org/10.1210/jc.2014-1690

44. Anic GM, Albanes D, Rohrmann S et al (2016) Association between serum 25-hydroxyvitamin D and serum sex steroid hormones among men in NHANES. Clin Endocrinol (Oxf) 85(2):258–266. https://doi.org/10.1111/cen.13062

45. Wehr E, Pilz S, Boehm BO, März W, Obermayer-Pietusch B (2010) Association of vitamin D status with serum androgen levels in men. Clin Endocrinol (Oxf) 73(2):243–248. https://doi.org/10.1111/j.1365-2265.2009.03777.x

46. Nimpfisch K, Platz EA, Willett WC, Giovannucci E (2012) Association between plasma 25-OH vitamin D and testosterone levels in men. Clin Endocrinol (Oxf) 77(1):106–112. https://doi.org/10.1111/j.1365-2265.2012.04332.x

47. Yang B, Sun H, Wan Y et al (2012) Associations between testosterone, bone mineral density, vitamin D and semen quality in fertile and infertile Chinese men. Int J Androl 35(6):783–792. https://doi.org/10.1111/j.1365-2457.2012.01287.x

48. Zhao D, Ouyang P, de Boer IH et al (2017) Serum vitamin D and sex hormone levels in men and women: The Multi-Ethnic Study of Atherosclerosis (MESA). Maturitas 96:95–102. https://doi.org/10.1016/j.maturitas.2016.11.017

49. Pilz S, Frisch S, Koerke H et al (2011) Effect of vitamin D supplementation on testosterone levels in men. Horm Metab Res 43(3):223–225. https://doi.org/10.1055/s-0030-1269854

50. Kelme JW (2010) Arm and leg substrate utilization and muscle adaptation after prolonged low-intensity training. Acta Physiol (Oxf) 199(4):519–528. https://doi.org/10.1111/j.1748-1716.2010.02123.x

51. Koh HE, Nielsen J, Saltin B, Holmberg HC, Ortenblad N (2017) Pronounced limb and fibre type differences in subcellular lipid droplet content and distribution in elite skiers before and after exhaustive exercise. J Physiol 595(17):5781–5795. https://doi.org/10.1113/jp274462

52. Van Hall G, Jensen-Urstad M, Rosdahl H, Holmberg HC, Saltin B, Calbet JA (2003) Leg and arm lactate and substrate kinetics during exercise. Am J Physiol Endocrinol Metab 284(1):E193–205. https://doi.org/10.1152/ajpendo.00273.2002
54. MacLaughlin J, Holick MF (1985) Aging decreases the capacity of human skin to produce vitamin D3. J Clin Invest 76(4):1536–1538. https://doi.org/10.1172/JCI112134

55. Strollo SE, Caserotti P, Ward RE, Glynn NW, Goodpaster BH, Strotmeyer ES (2015) A review of the relationship between leg power and selected chronic disease in older adults. J Nutr Health Aging 19(2):240–248. https://doi.org/10.1007/s12603-014-0528-y

**Publisher’s Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.